Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Small Cell Lung Carcinoma 5Sarcoma, Ewing 3Sarcoma 3Endometrial Neoplasms 3Neoplasms 2Stomach Neoplasms 1SCLC, Extensive Stage 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Temozolomide 6Irinotecan 6Vincristine 3PM 01183 3Nivolumab 3X-Rays 2Cyclophosphamide 2temsirolimus 1talazoparib 1surufatinib 1silmitasertib 1seclidemstat 1rubitecan 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1irinotecan sucrosofate 1eribulin 1entrectinib 1efineptakin alfa 1dinutuximab 1copanlisib 1bempegaldesleukin 1anlotinib 1alovudine 1abemaciclib 1Zoledronic Acid 1Trabectedin 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Ewing × PM 01183 × Clear all
NCT05918640 2026-03-31

LiFFT

Children's Hospital of Philadelphia

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Neoplasms, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor

NCT05734066 2026-02-03

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Jazz Pharmaceuticals

Phase 1/2 Recruiting
60 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT05042934 2022-02-10

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡